BIOStartr Blog

                                           

Subscribe to our weekly BIOStartr Newsletter

Get your weekly update on BIOStartr and the biotech scene

* indicates required

 

 

 

Today’s noteworthy biotech

Design DNA that works as predicted

GenoFAB is rewriting the way DNA is written – Introducing GenoCAD by GenoFAB

Rule-based Design

Like any language, DNA relies on grammar and context to make sense. GenoCAD allows you to write well-structured DNA sequences that a cell will understand.

Parts Libraries

Managing large database of DNA sequences is challenging. GenoCAD helps you import, organize, and share the information. Or you can use the parts available in our libraries.

Gene Expression Simulation

Don’t waste time on flawed constructs. GenoCAD will simulate the phenotype of your design in silico to make sure it works the way you want it to.


With hundreds of users and tens of thousands of parts – and more coming every day – GenoCAD is the leader in streamlined DNA construct design.


source: http://genofab.com

BIOStartr screens the biotech scene

Personalized drug combination for brain cancer patients

What if effective treatment combinations already exist and doctors just need help finding them?

Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.

Read more about Notable Labs on techcrunch.


source: http://www.notablelabs.com

 

On the BIOStartr radar

DNA and Serendipity – biotech instead of awkward first dates?

Love At First Swab is a genetic matchmaking experiment based on science of sex appeal, where users remain anonymous until they interact offline.

  1. Love At First Swab takes swab samples from users
  2. Love At First Swab analyses the DNA region responsible of attraction/chemistry
  3. Love At First Swab invites potential partners to a physical space where they interact via scientific games.

Love At First Swab looks at your DNA and quantifies it for potential matches. A part of your DNA defines how attracted you will be to a potential partner. Love At First Swab will analyze this region to generate your compatibility score.


source: http://loveatfirstswab.com

Weekly Wednesday Newsflash – get news from the biotech and startup scene on BIOStartr

What’s new in biotech in the week from 19 March – 25 March 2015? BIOStartr provides you with a short review of last week’s biotech news.

Sign up for our newsletter to receive the whole BIOStartr story weekly!

  • 03 | 25 | 15
    Biotech bootcamp: Scientific start-ups learning lessons from Silicon Valley –  read more (nature)


  • 03 | 24 | 15
    Biotech startup to fight diabetes on the cellular front – read more (The Boston Globe)


  • 03 | 23 | 15
    Back to its future: Biogen drops Idec from corporate name – read more (The Boston Globe)

    All about the topical issue: Is this a biotech bubble? – see the discussion (FierceBiotech)


  • 03 | 19 | 15
    How the weaker € Is affecting biotech earnings – read more (24/7 Wall St.)

    When in doubt, spell it out: Translating tech to biotech – read more (Forbes)

    Google’s mystery biotech Calico partners with the Broad on aging-related drugs – read more (FierceBiotech)


Weekly Wednesday Newsflash – get news from the biotech and startup scene on BIOStartr

What happpened in the week from 12 March – 18 March 2015? BIOStartr provides you with a short review of last week’s biotech news.

Sign up for our newsletter to receive the whole BIOStartr story weekly!

  • 03 | 18 | 15
    Cambridge biotech firm raises $43 million for fatty liver drug – read more (The Boston Globe)
  • 03 | 17 | 15
    Can biotech come from behind in Nasdaq’s March Madness? –  read more (Forbes)

    Startups, beware of the seed-funding surge trap! – read more (Entrepreneur)
  • 03 | 16 | 15
    Peter Thiel, first large investor in Facebook, now turning to biotech – read more (MIT Technology Review)

    Biotech CEOs: Who is going to be the right fit for a biotech startup? – read more (Forbes)
  • 03 | 13 | 15
    Bristol-Myers heads back to the FDA with its long-delayed hep C drug – read more (FierceBiotech)
  • 03 | 12 | 15
    23andMe dives into biotech with Genentech R&D star Richard Scheller on board – read more (FierceBiotech)

Weekly Wednesday Newsflash – get news from the biotech and startup scene on BIOStartr

What’s the news in biotech in the week from 05 March – 11 March 2015? BIOStartr provides you with a short review of last week’s biotech news.

  • 03 | 11 | 15
    Does legal approval of biosimilars threaten biotech? – read more  (StreetWise Journal)
  • 03 | 10 | 15
    Apple’s unveiling of ResearchKit destined to disrupt biomedical research – read more (Politico)

    What’s the next big biotech target in the multibillion-dollar M&A game? – read more (FierceBiotech)
  • 03 | 09| 15
    Protection without a vaccine – immunoprophylaxis by gene transfer – read more (New York Times)
  • 03 | 07 | 15
    First Copycat Biotech Drug Spurs $250B Obamacare Savings – read more (Forbes)
  • 03 | 05 | 15
    How biotech can help feed the planet – read more (Forbes)

    Baxter buys German biotech SuppreMol for €200 million – read more (PharmaTimes)

Weekly Wednesday Newsflash – get news from the biotech and startup scene on BIOStartr

Which happenings in biotech arrested attention in the week from 26 February – 04 March 2015? BIOStartr provides you with a short review of last week’s biotech news.

  • 03 | 04 | 15
    Bristol-Myers Squibb bets $975 Million on Bavarian Nordic’s Prostate Cancer Vaccine read more (BioSpace)
  • 03 | 03 | 15
    Only the paranoid biotechs will survive – read more (Forbes)

    Merck touts a bright future in biosimilars with a stable of would-be blockbusters – read more  (FierceBiotech)
  • 03 | 02 | 15
    China biotech makes FDA ‚breakthrough‘ for HIV drug – read more (FierceBiotech)

    Array BioPharma Gains $85M from Novartis in Deal for Cancer Compounds – read more (Genetic Engineering & Biotechnology News)
  • 02 | 28 | 15
    Venture funding for biotech startups is seeing an uptick – read more (Dallas News)
  • 02 | 27 | 15
    AstraZeneca Launches $40M Early-Stage Anti-Infectives R&D Unit – read more (Genetic Engineering & Biotechnology News)

    Novartis looks to squelch neuro worries over its would-be cardio blockbuster – read more (FierceBiotech)
  • 02 | 26 | 15
    Is a renaissance in surging biotechs underway? – read more (Forbes)

    Actavis wins FDA approval for a new ’superbug‘ antibiotic – read more (FierceBiotech)

Weekly Wednesday Newsflash – get news from the biotech and startup scene on BIOStartr

What moved the biotech industry in the week from 17 – 25 February 2015? Be up to date with BIOStartr’s biotech news.

  • 02 | 25 | 15
    Can Neil Woodford reignite the U.K.’s taste for biotech investments? – read more (FierceBiotech)
  • 02 | 24 | 15
    Venture Capitalists love biotech right now – read more (MIT Technology Review)

    Italian biotech Chiesi gains the first ever marketing approval for its stem cell therapy Holoclar for EU market – read more (European Biotechnology News)
  • 02 | 23 | 15
    Merck bets $450M on ‚Old School‘ biotech From NGM – read more (Forbes)

    Why you should start thinking like an entrepreneur – read more (The Fiscal Times)
  • 02 | 20 | 15
    IndieBio will accelerate synthetic Biology to tech startup speed – read more (Forbes)
  • 02 | 19 | 15
    The biotech sector is exploding by almost every measure. Will the bubble burst someday? – read more (Quartz)

    Ubiquitous Biotech in a time of ignorance – read more (Huffington Post)
  • 02 | 18 | 15
    Novartis makes concerted push into Israeli biotech startup scene – read more (FierceBiotech)

BIOStartr is the first digital accelerator for Biotechs.

At BIOStartr we believe Biotech is the future.The biotech sector is rapidly developing and we are developing with it. While others may believe that biotech is a risky branch with slower returns compared to other evolving technologies such as software and tech, we can’t say we agree. In our opinion, the world is just learning how to adapt to this amazing branch of technology. In fact, Biotech start-ups have a higher rate of success than their tech counterparts. Here at BIOStartr we even offer free services for your Biotech (read more here). Once you are ready to rock, our platform will help you find the best investor match for your project. Let us give you a boost and accelerate your business – only digitally.

BIOStartr is the new gateway for Biotechs to make valuable contacts.

We help to overcome recurring financing challenges in biotech by globalizing the sector. BIOStartr is the first digital accelerator for Biotechs. Investors, incubators and potential partners are now conveniently located – at BIOStartr.com!  Recurring financial challenges plague the Biotech sector. Our goal is to globalize the branch and lower risk for both, Biotechs and Investor. Go global, we have.

...7891011